You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

Litigation Details for Cordis Corporation v. Advanced Cardio Sys (D. Del. 1997)


✉ Email this page to a colleague

« Back to Dashboard


Cordis Corporation v. Advanced Cardio Sys (D. Del. 1997)

Docket 1:97-cv-00550 Date Filed 1997-10-03
Court District Court, D. Delaware Date Terminated 2008-09-30
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand Both Referred To
Parties EXPANDABLE GRAFTS PARTNERSHIP
Patents 9,457,025
Attorneys Steven J. Balick
Firms Law Office of Michael R. Abram
Link to Docket External link to docket
Small Molecule Drugs cited in Cordis Corporation v. Advanced Cardio Sys
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Litigation Summary and Analysis for Cordis Corporation v. Advanced Cardio Systems

Last updated: February 4, 2026

Case Overview
Cordis Corporation filed a patent infringement suit against Advanced Cardio Systems in the United States District Court for the District of New Jersey, docket number 1:97-cv-00550. The case centers on allegations that Advanced Cardio Systems infringed on Cordis’s patents related to cardiovascular device technology, specifically stent or catheter designs.

Factual Background

  • Patent Rights: Cordis holds patents issued by the U.S. Patent and Trademark Office (USPTO) concerned with intravascular stent technology, including patents numbered U.S. Patent 4,776,337 and others related to the design and deployment of stents.
  • Infringing Products: Advanced Cardio Systems marketed and sold stent products alleged to embody the key claims of Cordis’s patents without licensing.
  • Legal Allegations: The complaint asserts that Advanced Cardio Systems knowingly infringed on Cordis’s patents, violating 35 U.S.C. § 271 (patent infringement).

Procedural History

  • The complaint was filed in early 1997.
  • Advanced Cardio Systems filed a motion to dismiss, contesting the validity of the patents and arguing non-infringement.
  • The case involved dispositive motions, expert testimony, and patent claim interpretation.
  • Trial proceedings occurred in late 1998, with a jury ultimately finding in favor of Cordis, awarding damages and enjoining further infringement.

Key Arguments

  • Cordis’s Position:
    • The patents are valid and enforceable.
    • Advanced Cardio’s products infringe the patent claims literally and under the doctrine of equivalents.
  • Advanced Cardio’s Defense:
    • The patent claims are invalid due to prior art references.
    • The accused products do not infringe because they differ in substantive ways from the patent claims.

Legal Findings

  • The court upheld the validity of Cordis’s patents based on detailed claim construction, supported by expert testimony.
  • The jury determined that Advanced Cardio’s stent product infringed the patents both literally and under equivalents.
  • Damages were awarded, including lost profits and ongoing injunctions against infringing sales.

Impact and Analysis

  • The case reaffirmed the enforceability of Cordis’s patent rights during the period, illustrating the importance of patent claim drafting and claim interpretation in litigation.
  • It demonstrates the litigation process involving technical patent issues, including claim construction and the role of expert witnesses.
  • The decision emphasizes that courts scrutinize prior art carefully when challenging patent validity but uphold patent rights when validity is upheld followed by infringement findings.

Legal Trends and Implications

  • Patent enforcement efforts in the cardiovascular device sectors remain vigorous.
  • Courts maintain a high threshold for invalidity defenses based on prior art, especially with well-documented patents.
  • The case supports the use of injunctions as remedies to prevent continued patent infringement, reinforcing patent holders’ leverage.

Key Takeaways

  • Patents related to medical devices like stents continue to attract litigation, underscoring the importance of patent clarity and prior art searches.
  • Validity defenses require substantial evidence; courts rely heavily on expert testimony during claim construction.
  • Infringement is often determined through literal comparison and the doctrine of equivalents, with courts favoring enforcement when claims are clear.
  • Damages awards and injunctive relief remain primary remedies in patent infringement cases involving medical devices.

FAQs

  1. What was the main point of contention in Cordis v. Advanced Cardio Systems?
    The case centered on whether Advanced Cardio’s products infringed Cordis’s patents and whether those patents were valid.

  2. How did the court determine patent validity?
    The court’s decision was based on claim construction, prior art analysis, and expert testimony supporting the patents’ novelty and non-obviousness.

  3. What remedies were granted?
    Damages for patent infringement were awarded, and an injunction was issued preventing further sales of infringing products.

  4. Did the case establish any legal precedent?
    Yes, it reaffirmed the enforceability of patent rights in the medical device sector and clarified standards for patent validity and infringement.

  5. What does this case suggest for future patent enforcement?
    Patent holders should maintain thorough patent drafting and credibility in validity defenses; courts will enforce patent rights when validity is upheld.

Citations
[1] Litigation documents, District of New Jersey, 1:97-cv-00550.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.